Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mesenchymal stromal cells lower platelet activation and assist in platelet formation in vitro
Avital Mendelson, … , Xiuli An, Karina Yazdanbakhsh
Avital Mendelson, … , Xiuli An, Karina Yazdanbakhsh
Published August 22, 2019
Citation Information: JCI Insight. 2019;4(16):e126982. https://doi.org/10.1172/jci.insight.126982.
View: Text | PDF
Research Article Hematology Stem cells

Mesenchymal stromal cells lower platelet activation and assist in platelet formation in vitro

  • Text
  • PDF
Abstract

The complex process of platelet formation originates with the hematopoietic stem cell, which differentiates through the myeloid lineage, matures, and releases proplatelets into the BM sinusoids. How formed platelets maintain a low basal activation state in the circulation remains unknown. We identify Lepr+ stromal cells lining the BM sinusoids as important contributors to sustaining low platelet activation. Ablation of murine Lepr+ cells led to a decreased number of platelets in the circulation with an increased activation state. We developed a potentially novel culture system for supporting platelet formation in vitro using a unique population of CD51+PDGFRα+ perivascular cells, derived from human umbilical cord tissue, which display numerous mesenchymal stem cell (MSC) properties. Megakaryocytes cocultured with MSCs had altered LAT and Rap1b gene expression, yielding platelets that are functional with low basal activation levels, a critical consideration for developing a transfusion product. Identification of a regulatory cell that maintains low baseline platelet activation during thrombopoiesis opens up new avenues for improving blood product production ex vivo.

Authors

Avital Mendelson, Ana Nicolle Strat, Weili Bao, Peter Rosston, Georgia Fallon, Sophie Ohrn, Hui Zhong, Cheryl Lobo, Xiuli An, Karina Yazdanbakhsh

×

Figure 4

cMSCs cultured as a monolayer enhance platelet formation in vitro.

Options: View larger image (or click on image) Download as PowerPoint
cMSCs cultured as a monolayer enhance platelet formation in vitro.
CD34+...
CD34+ cells were differentiated for 8 days into megakaryocytes and then cultured with cMSCs, with bMSCs, or alone. (A) Expression of CD34 decreased by day 8 of culture, demonstrating differentiation from the stem cell state. (B) In all 3 groups, the presence of CD41a+ and CD42b+ cells, representative of mature megakaryocytes, could be detected by flow cytometry. (C) By day 12 of in vitro culture, proplatelet formation could be detected in the cMSC coculture group. Scale bar: 50 μm. Yellow arrows indicate proplatelets. (D) Immunofluorescent staining of the cMSC coculture group at day 12 of culture revealed the presence of CD41a+CD42b+ megakaryocytes. Scale bar: 50 μm. (E) By flow cytometry, the number of platelets formed was quantified per culture well. Significantly fewer platelets were formed when cMSCs were separated by a transwell, suggesting that contact is required between megakaryocytes and cMSCs. (F) The platelet efficiency, or platelets formed per megakaryocyte, was significantly higher in the cMSC group compared with the control group. (G) The amount of activated platelets expressing CD62P was quantified by flow cytometry. (H) Representative histogram of CD62P+ platelet population in cMSC group versus control. (I) Fold change of CD62P+ platelets relative to the control group (n = 10–15 for all cocultures). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. All quantitative data was analyzed by 1-way ANOVA with Tukey post hoc test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts